Shanghai Roundtable Maps the Gap Between China's Biotech Science and Its Capital Markets

More than 30 business leaders and investors from mainland China and Hong Kong filed into a Shanghai room this week with a shared complaint: the science is arriving faster than the money and the paperwork can carry it. The occasion was a South China Morning Post C-Suite roundtable titled "The Capital Lifecycle of the Healthcare Sector: From Seed to Post-Listing," staged alongside BioShanghai Week 2026 and backed by IHH Healthcare North Asia. On the panel sat Nisa Leung, founding managing partner of Aulis Capital, and Dr Kenneth Tsang, regional chief executive officer of IHH Healthcare North Asia. For anyone tracking where Asian wealth is trying to migrate next, the guest list and the timing say as much as the agenda.

The substance of the discussion was the distance between a laboratory result and a listed company. Participants set China's expanding biotech pipeline against the deeper funding pools and more mature public markets of the United States and Europe, and worked through the mechanisms companies now use to bridge that distance: out-licensing deals, so-called NewCo structures that park assets in fresh vehicles, and multi-regional clinical trials that let a single dataset serve several regulators. No transaction sizes or valuations were disclosed, and none should be inferred. The point was structural, not transactional. China can generate drug candidates; converting them into globally priced assets still depends on capital and approval channels largely built elsewhere.

Hong Kong occupied much of the conversation, and outsiders should understand why. The city has spent decades as the listing venue of choice for mainland companies shut out of New York or unwilling to wait for Shanghai. Now it is pitching itself as a testing ground for healthcare innovation, with participants weighing how takeover rules and delisting requirements shape the exit paths available to biotech founders. The backdrop is Hong Kong's first Five-Year Plan, which explicitly targets an international health and medical innovation hub. That ambition runs straight into a practical bottleneck: cross-boundary clinical data flows and coordinated trials. Without smoother movement of patient data and trial infrastructure, mainland patients remain separated from the international regulatory frameworks that would give their data global currency.

Artificial intelligence surfaced as a case study in capital discipline rather than hype. AI-driven drug discovery is compute-hungry and talent-hungry, and the roundtable heard a preference for strategic computing partnerships over heavy hardware investment — rent the capability, don't buy it. Running underneath was a blunter warning: research and development must anchor itself in validated clinical needs, not in whatever a model can generate cheaply. That is a notable shift in tone for a region that has often treated technological capability as its own justification.

For the family offices, sovereign funds and private capital that now treat Asian healthcare as a core allocation, the message is that the easy arbitrage is gone. The lifecycle the roundtable traced — financing, clinical validation, regulatory pathway, commercialisation, international market access — is a chain, and the weakest link sets the pace. Hong Kong's policy push and the mainland's pipeline are both real. Whether they connect is a question of data, rules and exits, not of scientific talent.

Watch the next twelve months for three signals: whether cross-boundary data arrangements move from principle to practice, whether NewCo and out-licensing structures become routine rather than novel, and whether Hong Kong's health hub plan acquires the regulatory teeth to match its language. Asia's healthcare capital story is no longer about whether the science can be funded. It is about whether the region can keep the value it creates.